A Phase 2 Study of RO7490677 In Participants With Myelofibrosis

Primary Myelofibrosis Clinical Trial

Official title:

A Phase 2, Prospective Study Of PRM-151 In Subjects With Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (Post-PV MF), Or Post-Essential Thrombocythemia MF (Post-ET MF)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01981850
• Other study ID #: BO42355
• Secondary ID: PRM-151G-1012015
• Status: Completed
• Phase: Phase 2
• Start date: October 1, 2013
• Est. completion date: July 10, 2020

Study information

• Verified date: December 2021
• Source: Hoffmann-La Roche
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

RO7490677 is an investigational drug that is being developed for possible use in the treatment of myelofibrosis (MF), a disease in which the bone marrow, which is the organ in the body that makes blood cells, is replaced by fibrosis, or excess scar tissue. The purpose of this study is to gather information on whether RO7490677 has an effect on the MF disease, whether it is safe in patients with MF, and how well it is tolerated.

Description:

Stage 1 of this study has completed. Stage 1 was an open-label, Simon two stage, Phase 2 study to determine the efficacy and safety of two different dose schedules of RO7490677 in participants with PMF and post ET/PV MF. There were two treatment cohorts, each assigned to one of two dose schedules receiving either single-agent RO7490677 or RO7490677 in combination with ruxolitinib. Participants were assigned to a weekly or every four week dosing schedule by the investigator. Stage 2 is a randomized, double-blind Phase 2 study to determine the efficacy and safety of three different doses of RO7490677 in participants with PMF and post ET/PV MF. Participants will be randomized to one of three doses: 0.3 mg/kg, 3.0 mg/kg or 10 mg/kg of RO7490677. This is the second stage of an adaptive design study as defined in FDA Draft Guidance for Industry: Adaptive Design Clinical Trials for Drugs and Biologics, February 2010. Modifications to dose levels, schedule, and regimen have been made in Stage 2 based on data from Stage 1.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 125
• Est. completion date: July 10, 2020
• Est. primary completion date: July 10, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Participants must be =18 years of age at the time of signing the Informed Consent Form (ICF);

2. Participants must voluntarily sign an ICF;

3. Participants must have a pathologically confirmed diagnosis of PMF as per the WHO diagnostic criteria or post ET/PV MF;

4. At least Grade 2 marrow fibrosis according to the WHO Grading of Bone Marrow Fibrosis;

5. Intermediate-1, intermediate -2, or high risk disease according to the IWG -MRT Dynamic International Prognostic Scoring System

6. A bone marrow biopsy must be performed within four weeks prior to Cycle 1 Day 1 treatment to establish the baseline fibrosis score;

7. Participants must not be candidates for ruxolitinib based on EITHER:

1. Platelet count < 50 x 10e9/L, OR

2. Hgb < 100 g/L, have received = 2 units PRBC in the 12 weeks prior to study entry, and be intolerant of or had inadequate response to ruxolitinib;

8. Participants must have an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-2. (Appendix F);

9. Life expectancy of at least twelve months;

10. At least four weeks must have elapsed between the last dose of any MF- directed drug treatments for myelofibrosis (including investigational therapies) and study enrollment;

11. Recovery to = Grade 1 or baseline of any toxicities due to prior systemic treatments, excluding alopecia;

12. Women of child bearing potential (WCBP), defined as a sexually mature woman not surgically sterilized or not post-menopausal for at least 24 consecutive months if =55 years or 12 months if >55 years, must have a negative serum pregnancy test within four weeks prior to the first dose of study drug and must agree to use adequate methods of birth control throughout the study. Adequate methods of contraception are outlined in the protocol.

13. Ability to adhere to the study visit schedule and all protocol requirements;

14. Must have adequate organ function as demonstrated by the following:

• ALT (SGPT) and/or AST (SGOT) = 3x upper limit of normal (ULN), or = 4 x ULN (if upon judgment of the treating physician, it is believed to be due to extramedullary hematopoiesis [EMH] related to MF);
• Direct bilirubin = 1.5 x ULN; or = 2x ULN (if upon judgment of the treating physician, it is believed to be due to EMH related to MF);
• Serum creatinine = 2.5 mg/dL x ULN.

Exclusion Criteria:

1. White blood cell count > 25 x 10e9/L or > 10% peripheral blood blasts;

2. Other invasive malignancies within the last 3 years, except non- melanoma skin cancer and localized cured prostate and cervical cancer;

3. History of stroke, unstable angina, myocardial infarction, or ventricular arrhythmia requiring medication or mechanical control within the last 6 months;

4. Presence of active serious infection;

5. Any serious, unstable medical or psychiatric condition that would prevent, (as judged by the Investigator) the participant from signing the informed consent form or any condition, including the presence of laboratory abnormalities, which places the participant at unacceptable risk if he/she were to participate in the study or confounds the ability to interpret data from the study;

6. Known history of human immunodeficiency virus (HIV), or known active hepatitis A, B, or C infection;

7. Organ transplant recipients other than bone marrow transplant;

8. Women who are pregnant or lactating.

Related Conditions & MeSH terms

• Polycythemia
• Polycythemia Vera
• Post-Essential Thrombocythemia Myelofibrosis
• Primary Myelofibrosis
• Thrombocythemia, Essential
• Thrombocytosis

Intervention

Biological:
• RO7490677
IV infusion

Drug:
• Ruxolitinib
IV infusion

Locations

Country	Name	City	State
Canada	The Princess Margaret Cancer Centre	Toronto	Ontario
Canada	Providence Health Care	Vancouver	British Columbia
France	Hospital Saint-Louis	Paris
Germany	University Medical Center RWTH Aachen	Aachen
Germany	Johannes Wesling Academic Medical Center	Minden
Israel	Hadassah Medical Centre	Jerusalem
Israel	Meir Medical Centre	Kfar Saba
Italy	Fondazione IRCCS Policlinico San Matteo	Pavia
Italy	Marche Nord Hospital	Pesaro
Netherlands	Radboud University Medical Center	Nijmegen
Netherlands	Erasmus Medical Center	Rotterdam	Zuid Holland
United Kingdom	Guy's and St. Thomas' Hospital	London
United States	University of Michigan	Ann Arbor	Michigan
United States	Emory Hospital	Atlanta	Georgia
United States	University of Maryland Medical Center	Baltimore	Maryland
United States	Dana-Farber Cancer Institute	Boston	Massachusetts
United States	MD Anderson Cancer Center	Houston	Texas
United States	Vanderbilt University Medical Center	Nashville	Tennessee
United States	Mount Sinai Medical Center	New York	New York
United States	Weill Cornell Medical Center	New York	New York
United States	Stanford Cancer Institute	Palo Alto	California
United States	Mayo Clinic Cancer Center	Phoenix	Arizona
United States	Wake Forest Baptist Medical Center	Winston-Salem	North Carolina

Sponsors (1)

Lead Sponsor	Collaborator
Hoffmann-La Roche

Countries where clinical trial is conducted

United States,  Canada,  France,  Germany,  Israel,  Italy,  Netherlands,  United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Stage 1 Main Phase: Maximum Drug Concentration (Cmax)	Cmax is the maximum observed RO7490677 plasma concentration.	Pre-dose on Cycles(C) 1, 2 and 6, Day(D) 1 and C1 D15. Each cycle is 28 days
Other	Stage 1 Main Phase: Time to Maximum Concentration (Tmax)	Time at which the maximum plasma concentration was observed.	Pre-dose on Cycles(C) 1, 2 and 6, Day(D) 1 and C1 D15. Each cycle is 28 days
Other	Stage 1 Main Phase: Area Under the Curve up to the Last Measurable Concentration (AUC0-last)	Area under the plasma concentration time curve from time 0 to time of last measurable plasma concentration.	Pre-dose on Cycles(C) 1, 2 and 6, Day(D) 1 and C1 D15. Each cycle is 28 days
Other	Stage 1 Main Phase: Area Under the Concentration-Time Curve Extrapolated to Infinity (AUC0-inf)	Area under the plasma concentration-time curve from 0-time extrapolated to infinity.	Pre-dose on Cycles(C) 1, 2 and 6, Day(D) 1 and C1 D15. Each cycle is 28 days
Other	Stage 1 Main Phase: Terminal Elimination Half-Life (T1/2)	Apparent terminal elimination half-life of RO7490677.	Pre-dose on Cycles(C) 1, 2 and 6, Day(D) 1 and C1 D15. Each cycle is 28 days
Other	Stage 1 Main Phase: Clearance (CL)		Pre-dose on Cycles(C) 1, 2 and 6, Day(D) 1 and C1 D15. Each cycle is 28 days
Other	Stage 1 Main Phase: Volume of Distribution (Vd)		Pre-dose on Cycles(C) 1, 2 and 6, Day(D) 1 and C1 D15. Each cycle is 28 days
Other	Percentage of Participants With Adverse Events (AEs) and Infusion Related Reactions (IRRs)	An AE was defined as any noxious, pathologic, or unintended change in anatomical, physiologic, or metabolic function as indicated by physical signs, symptoms, or laboratory changes occurring in any phase of a clinical study, whether or not considered investigational product-related. Pre-existing conditions which worsened during the study were also considered as adverse events. IRRs were considerd to be Adverse Events of Special Interest (AESI). Grading was completed according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE), version 4.0.	Baseline up until 6.75 years
Other	Percentage of Participants With Serious Adverse Events (SAEs) and AEs Leading to Study Drug Discontinuation	An SAE was defined as any AE that occurred at any dose the resulted in death; was life-threatening; required hospitalization or prolongation of existing hospitalizations; a persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions; a congenital anomaly or birth defect. An AE was defined as any noxious, pathologic, or unintended change in anatomical, physiologic, or metabolic function as indicated by physical signs, symptoms, or laboratory changes occurring in any phase of a clinical study, whether or not considered investigational product-related. Pre-existing conditions which worsened during the study were also considered as adverse events. Grading was completed according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE), version 4.0.	Baseline up until 6.75 years
Primary	Stage 1 Main Phase: Overall Response Rate (ORR)	ORR was defined as the percent of participants with a response according to the International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) criteria. This was defined as those participants who achieved clinical improvement (CI), partial remission (PR), or complete remission (CR) at a post-baseline assessment of treatment response OR had at least stable disease (SD) for three consecutive end-of-cycle response assessments (e.g. Day 1 of the subsequent cycle) in conjunction with improvement in the bone marrow fibrosis score relative to baseline by at least one grade at any time point during the period of stable disease.	Up until and including completion of 6 cycles. Each cycle is 28 days.
Primary	Stage 2 Main Phase: Bone Marrow Response Rate (BMRR)	Response rate was defined as the percent of participants with a reduction in bone marrow fibrosis by at least one grade according to World Health Organization (WHO) criteria from baseline to any time during the study. This was determined by a central adjudication panel of expert hematopathologists, blinded to participant, treatment, and time of biopsy.	Up until and including completion of 9 cycles. Each cycle is 28 days.
Primary	Stage 1 Main + Open-Label Extension (OLE): ORR	ORR was defined as the percent of participants with a response according to the IWG-MRT criteria. This was defined as those participants who achieved CI, PR, or CR at a post-baseline assessment of treatment response OR had at least SD for three consecutive end-of-cycle response assessments (e.g. Day 1 of the subsequent cycle) in conjunction with improvement in the bone marrow fibrosis score relative to baseline by at least one grade at any time point during the period of stable disease. Participants who achieved a clinical benefit in the main phase had the opportunity to remain on treatment. The determination of ORR in the main phase is outlined in the arms description below. Participants who didn't achieve a benefit had the opportunity to switch to a different dosing schedule in the OLE phase. The determination of ORR in the OLE phase is outlined in the arms descriptions below.	From cycle 1 day 1 up until cycle 6, day 29 (Main Phase). From cycle 7 day 1 up until study discontinuation or study termination, up to 83 cycles (OLE). Each cycle is 28 days.
Primary	Stage 2 Main + Open-Label Extension (OLE): BMRR	Defined as the percent of participants with a reduction in bone marrow fibrosis score by at least one grade according to WHO criteria at any time during the study. As determined by a central adjudication panel of expert hematopathologists, blinded to participant, treatment, and time of biopsy. Participants in the main phase had the opportunity to remain on treatment (as outlined in the arms description below). Participants also had the option to switch to the OLE phase after completing 9 cycles of the originally assigned treatment and receive PRM-151 10 mg/kg/Q4W (as outlined in the arms description below).	From cycle 1 day 1 up until cycle 9 day 29 (main phase). From cycle 10 day 1 up until study discontinuation or study termination, up to 51 cycles (OLE). Each cycle is 28 days.
Secondary	Stage 1 Main Phase: BMRR	Bone marrow response was defined as a reduction in bone marrow fibrosis score by at least one grade from baseline at anytime during the study.	Baseline, Weeks 12 and 24
Secondary	Stage 1 Main Phase: Modified Myeloproliferative Neoplasms Symptom Assessment Form Total Symptom Score (MPN-SAF TSS) Changes	The MPN-SAF TSS total symptom score was the sum of the following 10 items: Filling up quickly when you eat (early satiety), abdominal discomfort, inactivity, Problems with concentration, Worst fatigue, Night sweats, Itching, Bone pain, Fever and Unintentional weight loss last 6 months. The MPN-SAF Total Symptom Score had a possible range of 0 to 100, where a lower score was more favorable. The values reported are the change from baseline scores.	Baseline, beginning of each cycle (Cycle 2 onward). Each cycle is 28 days.
Secondary	Stage 2 Main Phase: BMRR	Response rate was defined as the percent of participants with a reduction in bone marrow fibrosis by at least one grade according to World Health Organization (WHO) criteria at any time during the study. This was determined by a central adjudication panel of expert hematopathologists, blinded to participant, treatment, and time of biopsy.	Up until and including completion of 9 cycles. Each cycle is 28 days.
Secondary	Stage 2 Main Phase: BMRR - Reduction of Bone Marrow Fibrosis by Visit	Reduction in bone marrow fibrosis score: Reduction of at least one grade from baseline. Bone marrow fibrosis grades according to WHO criteria (as determined by central adjudication).	Day 1 on Cycles 4, 7, 10 and Cycle 9 Day 29. Each cycle is 28 days.
Secondary	Stage 2 Main Phase: Duration of Bone Marrow Improvement	Duration of response was defined as time from first decrease from baseline >= 1 grade to time of return to baseline levels.	From first decrease from baseline of one grade to time of return to baseline levels, up to cycle 9 of 28-day cycles.
Secondary	Stage 2 Main Phase: Hemoglobin Improvement	Hemoglobin improvement was measured by the percent of participants with: Red cell transfusion independence (no transfusions for >= 12 consecutive weeks) OR 50% reduction in red blood cell (RBC) transfusions for >= 12 consecutive weeks OR percent of participants with >= 10 g/L and >= 20 g/L increase in hemoglobin for >= 12 consecutive weeks without transfusions (outcome parameter assessed was dependent on baseline hemoglobin/transfusion status).	Up until and including completion of 9 cycles. Each cycle is 28 days.
Secondary	Stage 2 Main Phase: Platelet Improvement	Platelet improvement was measured by the percent of participants with: Platelet transfusion independence (no transfusions for >= 12 consecutive weeks) OR 50% reduction in platelets transfusions for >= 12 consecutive weeks OR doubling of baseline platelet count for >= 12 consecutive weeks without platelet transfusions OR platelet count > 50 x 10e9/L for >=12 consecutive weeks without platelet transfusions OR doubling of baseline platelet count for >= 12 consecutive weeks without platelet transfusions OR platelet count > 25 x 10e9/L for >= 12 consecutive weeks without platelet transfusions (outcome parameter assessed is dependent on baseline platelet status).	Up until and including completion of 9 cycles. Each cycle is 28 days.
Secondary	Stage 2 Main Phase: Symptom Improvement	Symptom improvement was assessed as the percent of participants with 50% reduction in MPN-SAF TSS from baseline over time. The MPN-SAF TSS total symptom score was the sum of the following 10 items: Filling up quickly when you eat (early satiety), abdominal discomfort, inactivity, Problems with concentration, Worst fatigue, Night sweats, Itching, Bone pain, Fever and Unintentional weight loss last 6 months. The MPN-SAF Total Symptom Score had a possible range of 0 to 100, where a lower score was more favorable.	Up until and including completion of 9 cycles. Each cycle is 28 days.
Secondary	Stage 2 Main Phase: Percentage of Participants With Complete Response (CR), Partial Response (PR), Clinical Improvement (CI), Stable Disease (SD), and Progressive Disease (PD) According to IWG-MRT Criteria	Best Overall Response: (CR, PR, CI), SD and PD according to the IWG-MRT Criteria.	Up until and including completion of 9 cycles. Each cycle is 28 days.